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AbstrACt
Introduction With the widespread use of electronic health 
records and handheld electronic devices in hospitals, 
informatics- based antimicrobial stewardship interventions 
hold great promise as tools to promote appropriate 
antimicrobial drug prescribing. However, more research 
is needed to evaluate their optimal design and impact on 
quantity and quality of antimicrobial prescribing.
Methods and analysis Use of smartphone- based digital 
stewardship applications (apps) with local guideline 
directed empirical antimicrobial use by physicians will be 
compared with antimicrobial prescription as per usual as 
primary outcome in three hospitals in the Netherlands, 
Sweden and Switzerland. Secondary outcomes will include 
antimicrobial use metrics, clinical and process outcomes. 
A multicentre stepped- wedge cluster randomised trial will 
randomise entities defined as wards or specialty regarding 
time of introduction of the intervention. We will include 36 
hospital entities with seven measurement periods in which 
the primary outcome will be measured in 15 participating 
patients per time period per cluster. At participating 
wards, patients of at least 18 years of age using 
antimicrobials will be included. After a baseline period 
of 2- week measurements, six periods of 4 weeks will 
follow in which the intervention is introduced in 6 wards 
(in three hospitals) until all 36 wards have implemented 
the intervention. Thereafter, we allow use of the app by 
everyone, and evaluate the sustainability of the app use 6 
months later.
Ethics and dissemination This protocol has been 
approved by the institutional review board of each 
participating centre. Results will be disseminated via 
media, to healthcare professionals via professional training 
and meetings and to researchers via conferences and 
publications.
trial registration number  ClinicalTrials. gov registry 
(NCT03793946). Stage; pre- results.
IntroduCtIon
Antimicrobial drugs are an indispensable 
part of modern medicine, which depends on 
effective drugs for prophylaxis and treatment. 
Yet, only around 40%–70% of empiric antimi-
crobial regimens are considered appropriate 
with regard to their indication, the choice of 
agent, dosing or duration.1–4 Inappropriate 
antimicrobial use enhances the risks of treat-
ment failure and side effects in the individual 
patient, and accelerates selection and trans-
mission of antimicrobial- resistant pathogens 
in healthcare settings and the community.5 
Many antimicrobial stewardship (AMS) inter-
ventions have been shown to increase appro-
priateness of antimicrobial drug prescribing.6
A software application (app), which is 
compatible with mobile electronic devices 
such as smartphones and tablets, and 
strengths and limitations of this study
 ► This study will be an international randomised, mul-
ticentre, clinical trial using a rigorous design and 
methodology to evaluate the impact of an antimicro-
bial stewardship smartphone application (app) for 
the hospital setting.
 ► The app can easily be adapted to local guidelines 
which is a key feature for potential future use in oth-
er settings.
 ► The primary outcome is appropriate empiric anti-
microbial therapy. The study is conducted in three 
hospitals with relatively high rates of appropriate 
antibiotic use, which may theoretically lead to a 
higher risk of a negative trial.
 ► In this cluster randomised trial, wards/specialties 
are the unit of randomisation and there is a risk 
of contamination through physicians changing be-
tween wards or among specialties, although this 
risk is lower than for a single- centre randomised 
trial. Restricted access to the software and track-
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Table 1 Characteristics of the participating centres
Name
Geneva University 
Hospitals Erasmus MC Rotterdam Uppsala University Hospital
Website www.hug-ge.ch/en/ https://www.erasmusmc.nl/ https://www.akademiska.se/en/
Abbreviation HUG EMC UUH
City Geneva Rotterdam Uppsala
Country Switzerland The Netherlands Sweden
Care level Primary and tertiary care Tertiary care Tertiary care
Academic affiliation Yes Yes Yes
Number of beds About 1 900 900 About 1 000
Availability of 
antibiotic guidelines
Paper format and PDF Website containing local guidelines. 
Updated every 2 years. Guidelines 
are based on the national guidelines 
of SWAB
Local guidelines in paper format and 
online (pdf). Updated every 2–3 years.
Updated every 2 years National guidelines provided by STRAMA 
available online and in app format, not 
routinely used at UUH.
Integrated into the EHR in 
some units in the context 
of a different study (Trial 
registration number: 
NCT03120975); COMPASS 
units not participating in this 
study
  
Current standard of 
care antimicrobial 
stewardship
 ► On demand ID 
consultations
 ► On demand ID consultations  ► On demand ID consultations
 ► Review of all positive 
blood cultures
 ► Daily rounds on Intensive care 
units, weekly rounds on all units
 ► Daily rounds on intensive care units
 ► Daily rounds on some 
units
 ► Review and feedback for certain 
antibiotics
 ► Adapted information and feedback to 
physicians at major departments 1–2 
times per year
 ► Approval required for 
certain antibiotics
 ► Approval required for certain 
antibiotics
  
   ► Review of all positive blood 
cultures
  
EHR, electronic health record; ID, infectious disease; STRAMA, Swedish strategic programme against antibiotic resistance; SWAB, 
Dutch working party on antibiotic policy.
increases the availability of existing national and local 
antibiotic guidelines plus local antibiograms, may 
improve antimicrobial prescribing, reduce medication 
errors and ultimately improve patient outcome. Due to its 
highly customisable nature, a digital app has the potential 
to become an effective AMS tool in all countries.
Mobile- software apps seem particularly interesting for 
the purpose of AMS, since they do not require access to 
electronic health records (EHRs) or computerised physi-
cian order entry systems, that are costly, difficult to main-
tain and not easily customisable. Most healthcare workers 
own a smartphone and often use it to access information 
to assist in their treatment decisions.7 8 The vast majority 
of available apps developed to support prescription of 
medicines are limited to knowledge content and do not 
provide decision support algorithms. Further, they have 
rarely been evaluated in clinical trials.9 To date, most 
reported digital AMS interventions are single- centre 
studies with limited internal validity due to methodolog-
ical limitations and uncertain external validity.4 10 11
In the present study, we will evaluate the implemen-
tation and impact of a smartphone- based software app 
(the AB- Assistant, Spectrum, Calgary, Canada) adapted 
to local conditions in an international clinical trial using 
a stepped- wedge cluster randomised design and appro-




This study will be conducted in three academic, tertiary 
care hospitals in Europe: Erasmus University Medical 
Center, Rotterdam, the Netherlands; Uppsala University 
Hospital, Uppsala, Sweden and Geneva University Hospi-
tals, Geneva, Switzerland (table 1).
study design
We plan to conduct an international, multicentre, 
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Table 2 PICOT of the study question
Population
Physicians involved in antimicrobial 
prescribing decisions for hospitalised adult 
patients in the participating centres
Intervention Making a smartphone application with 
antimicrobial treatment recommendations 
available to physicians mentioned above
Comparator Standard- of- care antimicrobial stewardship
Outcome Appropriateness of empiric antimicrobial 
prescribing based on predefined criteria
Time 12 months consisting of a 6 months 
introduction period with 6 months follow- up 
to assess sustainability
Figure 1 Study design. In all time periods (total of 7) there is an uptake period of 2 days and a measure period of 26 days. 
During the baseline period only a measure period of 2 weeks will be performed.
making a smartphone app for AMS (Spectrum) can 
improve the appropriateness of antimicrobial prescribing 
in hospitalised patients. Table 2 illustrates the study ques-
tion according to the Population, Intervention, Compar-
ator, Outcome and Time (PICOT) framework.
In total, 36 medical and surgical entities (defined as 
wards (Sweden) or specialties (Switzerland, The Neth-
erlands) will be included in the study using a stepwise 
design with six entities (two entities per participating 
hospital) 4- weekly at six introduction moments (figure 1). 
The primary outcome is appropriateness of empiric anti-
microbial prescriptions assessed prior to implementa-
tion and up to 12 months after the intervention (after 6 
months free use of the app). Empiric therapy is defined 
as1 treatment started based on clinical evaluation before 
culture results are known,2 the duration of treatment 
is longer than 24 hours (from the moment of prescrip-
tion) and3 the treatment is not specifically recorded as 
prophylactic. Initial targeted therapy for which there is a 
local guideline available (eg, Clostridium difficile) may be 
assessed for appropriateness.
The entities will be randomised as to the time period of 
making the app available (see the Intervention section). 
The order of implementation will be determined by a 
computer- generated list of random numbers programmed 
by a statistician otherwise not involved in the trial and AMS 
activities. Randomisation will be stratified by the type of 
specialty (medicine, surgery, etc). After a baseline period 
of 2- week measurements, six periods of 4 weeks will follow 
in which the intervention is introduced in six entities (in 
three hospitals) until all entities have implemented the 
intervention. We plan to include 36 entities in total (see 
sample size calculation below) during the six introduc-
tion moments and at the end of the inclusion time we 
will allow the use of the app by everyone, also wards/
specialties not included in the study. In this way, the trend 
in appropriate antimicrobial use can be monitored per 
ward/specialty and the decrease of antimicrobial use and 
appropriateness of empirical antimicrobial therapy can 
be followed during the stepwise implementation.12 At 12 
months (after 6 months free use of the app) we will have a 
2- week measurement period to evaluate the sustainability 
of the intervention. The study will start between February 
2020 and June 2020, and end 12 months later.
Justification of the stepped-wedge cluster randomised study 
design
The stepped- wedge cluster randomised design was chosen 
after considering several advantages and disadvantages 
of randomisation at the patient, physician, specialty and 
ward level. Patients are the ‘classic unit’ of randomisa-
tion and outcomes are often assessed at the patient level. 
However, there is a large risk of contamination of the 
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Figure 2 Scheme of potential contamination. The potential contamination in a hospital, in and between wards, physicians and 
patients
many different physicians (see figure 2). Furthermore, 
the study intervention targets physicians and not patients, 
therefore precluding randomisation at the patient level 
as an option. Randomisation at the physician- level is, 
however, equally problematic since prescribing deci-
sions in hospitals are often made by teams of physicians, 
making it difficult to assign a decision to a specific indi-
vidual physician and introducing the risk of contami-
nation between physicians within a team. We therefore 
decided to use the wards/specialty as entity of randomi-
sation since it minimises the risk of contamination and 
reflects ‘real- life’ AMS in hospitals where interventions 
are usually implemented at a ward/specialty level.
The stepped- wedge design, which involves the 
randomised and sequential rollout of the intervention to 
clusters over time, was chosen because it can model and 
adjust for underlying temporal trends and results in all 
clusters having access to the intervention at the end of 
the rollout period which seems desirable from an AMS 
perspective.13
study population
In our study, the intervention will be targeted at physicians 
that prescribe antimicrobials. To avoid possible contami-
nation, the prescribers will be randomised at the ward/
specialty level and not individually (see above). Process 
parameters will be determined in physicians who have 
been randomised to use the app as per the process indi-
cated above. Outcome parameters such as appropriate 
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Figure 3 Interface of the AB- assistant app. On the left the Home screen is shown. In the middle checkboxes are shown to 
guide the user to the correct therapy for Meningitis. The right screen shows details about Amoxicillin- Clavulanate regarding 
dosing and general spectrum of activity.
at participating wards (control and intervention) who 
meet the following criteria: being a medical or surgical 
specialty patient at least 18 years of age for whom antimi-
crobial drugs are prescribed.
Intervention
The Spectrum app, available for iOS and Android and on 
the web, has been developed in Canada ( www. spectrum. 
app) and is now being used in over 50 hospitals, mainly in 
Canada and the USA. The app has been developed with 
the help of human factor experts and integrates multiple 
resources into a unified user- friendly interface for use 
at point- of- care to improve antimicrobial prescribing 
(figure 3).
For the purpose of this study the app and the content 
management system were extended to also support 
languages other than English (French, Dutch and 
Swedish) and will be used for prescribing guidelines, 
pathogens, antimicrobial drugs and antibiograms. App 
content such as local guidelines, information regarding 
antimicrobial drugs, and micro- organisms of each hospital 
was entered by investigators of the Dutch, Swiss and 
Swedish hospitals (RH, GC, BH and APL). App content 
is identical to content of the local guidelines if these are 
published on a website. Minor discrepancies may occur if 
the local guidelines are published in a digital document 
(ie, PDF) or on paper. The app can be more up to date 
in those cases.
The allocation of the timing to introduce the app will 
be concealed to the participating cluster up until 2 weeks 
before initiating use of the intervention. At the start of 
the intervention physicians on the intervention ward(s) 
will be informed about the function and content of the 
app. During the trial, only physicians on the intervention 
wards will be whitelisted to be able to use the app. Access 
to the app will be centrally withdrawn if a physician leaves 
the intervention ward (eg, to work on a different (ie, non- 
intervention) ward). The conventional route of guide-
lines (eg, portable document formats (PDF), website or 
printed booklet) will still be available at all times. Physi-
cians can freely choose between the app and the conven-
tional route. Physicians on control wards will only be able 
to access the guidelines using the conventional route.
Patient and public involvement
No patients or public have been included in the study 
design.
outCoME PArAMEtErs
Outcome parameters (table 3) will be monitored using 
a digital case report form (CRF) (online supplementary 
appendix 1) in the software application OpenClinica.14
Primary outcome parameter
Appropriateness of empiric antimicrobial therapy 
expressed as number and percentage of appropriate 
treatment episodes compared with all assessed treatment 
episodes.
Definitions for the primary outcome are:
 ► Antimicrobial drugs assessed are anatomical thera-
peutic chemical (ATC) classes J01, J02, J03, J04, J05 
(excluding anti- HIV drugs), P01, P02 and P03.
 ► Treatment episodes are defined as the duration of 
treatment given for a specific infectious episode with 
gaps of treatment of no longer than 1 day.
 ► Treatments are antimicrobials started during the 
measurement period at the participating entity. If a 
treatment was started within 24 hours before transfer 
in the emergency room or other ward and has not 
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Table 3 Secondary study parameters/endpoints and other study parameters
Outcome type Examples Data source
Quantitative antimicrobial 
use
 ► Total prescription of antimicrobial drugs1 in DDD/admission, DDD/PD, 
DOT/PD and DOT/admission
 ► EHR
 ► Total prescription of broad spectrum and restricted antimicrobial drugs 
in DDD/admission
 ► Administrative data
 ► Total prescription of antimicrobial drugs per AWaRe category19 in DDD/
admission
  
 ► Antimicrobial costs   
Patient  ► Length of hospital stay  ► EHR
Related  ► In hospital mortality within 30 days after admission (all cause)  ► Administrative data
   ► Unplanned hospital readmissions within 30 days after discharge   
   ► Transfer to intermediate care or ICU within 30 days after admission   
Microbiologic and HAI  ► Incidence of healthcare facility onset Clostridium difficile  ► EHR
 ► Incidence clinical cultures with multi- drug resistant organisms (MRSA, 
ESBL- E, CPE, VRE, multidrug resistant Pseudomonas aeruginosa) 
denominated per 1000 PD and admission
 ► Microbiology database
   ► Infection control surveillance data
Physician related  ► Uptake of the AB- assistant (total users and number of sessions per 
user, time spent per session, time spent per screen, number of times 
each screen is viewed)
 ► Content Management System
 ► Differences in uptake between centres  ► Content Management System
 ► Actual use of app and experiences while using it  ► Survey
Other outcomes  ► Number of infectious diseases consultations  ► EHR
1. Antimicrobials belonging to Anatomical Therapeutic Chemical Classification System class J01, J02, J03, J04, J05 (excluding anti- HIV drugs), P01, 
P02 and P03, oral vancomycin (A07AA09) and fidaxomicin (A07AA12).
AWaRe, access, watch, reserve; CMS, content management system; CPE, carbapenemase- producing enterobacteriaceae; CRE, carbapenem- 
resistant enterobacteriaceae; DDD, defined daily dose ; DOT, days of therapy; EHR, electronic health record; ESBL- E, extended- spectrum beta- 
lactamase- producing E; HAI, hospital acquired infections; ICU, intensive care unit; MRSA, methicillin resistant staphylococcus aureus; PD, patient- 
days.
ward, the treatment will be considered in accordance 
with the choice of the ward physician.
 ► Treatments are in patients either newly admitted 
to the participating entities or already hospitalised 
during the preintervention period.
 ► Appropriateness of empiric therapy includes choice, 
route and the dose of the antimicrobial drugs.
 ► Appropriateness of therapy is in concordance with 
local treatment guidelines. If no guidelines are avail-
able, or if the treatment deviates from the guidelines 
or if treatment is guideline concordant but treatment 
should have deviated from the guideline (eg, because 
of allergies, colonisation with multidrug- resistant 
bacteria, other microbiological results, interactions, 
comorbidities or recent exposure to antimicrobials), 
anonymised cases will be discussed between two inde-
pendent local infectious disease (ID) physicians. If 
they do not agree a third independent local ID physi-
cian will be consulted to adjudicate.
 ► For each patient only the first treatment episode 
during the measurement period will be evaluated. For 
patients treated for >1 infection (eg, pneumonia and 
C. difficile infection) appropriateness will be assessed 
for all infections combined (eg, if treatment is appro-
priate for C. difficile infection but inappropriate for 
pneumonia the treatment would be categorised as 
inappropriate).
secondary outcome parameters
 ► Total prescription of antimicrobial drugs on the 
cluster- level expressed as defined daily dose (DDD) 
and day of therapy (DOT) denominated by patient- 
days and admission; subcategories by type of antimi-
crobial (antibiotic, antifungal, etc), WHO Access, 
Watch, Reserve (AWaRe) categories and restricted 
antimicrobial drugs (table 3).
 ► Clinical secondary outcomes: length of hospital stay, 
in hospital mortality and readmissions within 30 days 
after discharge, incidence/prevalence of key antimi-
crobial resistant (AMR) pathogens such as C. difficile.
 ► Process parameters of the intervention: penetration 
of the AB- assistant (total users and number of use of 
app), and uptake differences between centres.
Along side the randomised controlled trial (RCT), an 
uptake analysis will be performed to assess actual use of 
the app as well as an evaluation of use.
uptake analysis
A number of parameters regarding use of the app will 
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to authorised users at each site. These include number 
of monthly users and monthly sessions, number of times 
each antimicrobial, pathogen or clinical pathway screen 
is viewed, use by hospital, department and medical 
specialism. These data will enable in- app behaviour to 
be correlated with actual prescribing behaviour on ward 
level and site- wide basis, thereby strengthening the associ-
ation of the intervention to observed outcomes.
EvAluAtIon of usE
Insufficient user friendliness and lack of integration 
into the workflow are key impediments to the uptake of 
IT- based AMS interventions. Therefore, we will evaluate 
the physicians’ experiences with the use of the app. After 
each introduction period all physicians of intervention 
wards will receive a questionnaire to collect information 
on experiences using the app. The questionnaire will be 
based on information from the literature,15 see online 
supplementary appendix 2.
blIndIng durIng EvAluAtIon of outCoME PArAMEtErs
Given the nature of the intervention and the primary 
outcome assessed it will be difficult to blind the outcome 
assessor. To assure that assessment bias is limited we will 
have a subset of outcomes (10%) assessed by an indepen-
dent investigator blinded to the study period.
stAtIstICAl MEthods
Baseline characteristics of patients (eg, gender, age, 
allergies and comorbidities), use of antimicrobial drugs, 
appropriate antimicrobial therapy and other outcome 
parameters will be described by entity.
To mitigate possible differences in time trends and 
baseline characteristics at patient and centre level, 
primary analysis will be by centre and effect estimates will 
be combined over centres using meta- analytic methods. 
These primary analyses will employ multivariable multi-
level logistic models with time periods as fixed effects to 
adjust for time trend and treatment as fixed effect to esti-
mate the OR of treatment. Entities (ward/specialty) will 
be included as a random effect to account for the correla-
tion of patients within entities, assuming this correlation 
is independent of time period of including the patient. 
Moreover, covariates will be included to adjust for age, 
gender, hospital and specialty (medical, surgical). Similar 
models but using (generalised) linear multilevel models 
will be used for continuous outcomes or incidence/rate 
outcomes.
Sensitivity analyses may include the following: adjusting 
for additional confounders if imbalance at baseline is 
present; investigating deviations from the assumption 
that the correlation of patients within entities is indepen-
dent of time period of including the patient; estimating 
differences in percentage (instead of odds ratios) using a 
(generalised) linear multilevel models with identity link 
and binomial error distribution and incorporating the 
three centres in one model.
Subgroup analysis for specialty and other factors as 
appropriate will be conducted.
sample size
By including 24 entities (wards/specialties) with seven 
measurement periods (including one baseline period) 
in which the primary outcome (appropriate empiric anti-
microbial drug use) will be measured in 15 participating 
patients per entity per time period and an assumed intra- 
entity correlation coefficient of 0.1, the study has a power 
of 81% to detect an absolute improvement in appropriate 
antimicrobial use by 10 percentage points from of 60% 
to 70%.16 To account for potential drop- outs or a lower 
inclusion rate, we aim to include 36 clusters in the three 
participating hospitals.
EthICs And dIssEMInAtIon
This protocol has been approved by the institutional 
review board (IRB) of each participating centre. Ethical 
approval has been obtained from the Medical Ethics 
Committee Erasmus MC, Rotterdam, the Netherlands, 
number MEC-2019–0172, the Swedish Ethical Review 
Authority, Uppsala, Sweden, number 2019-05075 and 
from the Commission cantonaled'éthique de la recherche, 
Geneva, Switzerland, number 2019-01061. Physicians will 
be informed about the app without obligation to use it, 
furthermore analysis of usage will be anonymous, there-
fore a waiver for informed consent for physicians has been 
asked. However, participating physicians will be asked for 
a digital informed consent the first time they use the app. 
To monitor patient data, consent will be asked according 
to the country legislation and IRB mandate.
dissemination
Results will be disseminated to healthcare professionals 
and researchers via presentations at national and inter-
national conferences and publications in peer- reviewed 
journals. Furthermore, we plan to have a workshop with 
interested healthcare workers after the end of the study 
to disseminate experiences and findings. The public will 
be informed through press releases.
General project data and metadata will be included in 
the supplementary data of published articles if needed, 
and/or shared through university repositories.
dIsCussIon And IMPlICAtIons
To date, few IT- based AMS interventions have been eval-
uated in randomised clinical trials.4 10 11 Clinical decision 
making by means of clinical decision support systems 
(CDSS) integrated in the EHR present the ‘gold stan-
dard’ of IT- based AMS. However, their widespread use 
has been limited by some major obstacles: (1) EHRs are 
still not universally implemented in all hospitals in high- 
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middle- income countries (2) even if an EHR is imple-
mented it usually lacks essential components for CDSS 
such as a computerised physician order entry system and 
(3) EHRs—especially those of commercial vendors—
have designs that are difficult to modify/adapt. By devel-
oping an ‘app’ as a software programme running on 
smartphones and other mobile devices such as tablets, an 
intermediate or complementary step to full CDSS may be 
offered. Spectrum is a smartphone- based digital steward-
ship app that is customisable to local guidelines by local 
AMS teams. In our stepped- wedge cluster randomised 
trial we will evaluate the impact of this app on appropriate 
antimicrobial prescribing in high- income countries. 
However, smartphone adoption is consistently strong 
in middle- income countries such as in the Caribbean 
and reached low- income countries in Africa.17 18 More 
and more healthcare workers have their own electronic 
devices (smartphone or tablets).7 AMS smartphone- 
based interventions can be made easily available, in high- 
income, low- income and middle- income countries. The 
ability of this app will make antibiotic prescription guide-
lines more accessible for physicians all over the world, 
thereby helping to fight AMR.
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